---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-016940"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2021-12-20T23:59:59+00:00"
generated_at: "2026-06-27T23:39:56.197574+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kala Pharmaceuticals promotes Todd Bazemore to President and COO, effective Dec 16, 2021

## Summary
- Todd Bazemore, COO since Nov 2017, appointed President and COO effective December 16, 2021.
- Mark Iwicki remains CEO and Chairman but no longer serves as President of the Company.
- No changes to Bazemore's compensation or compensatory plans in connection with the promotion.
- Bazemore has served on Pulmatrix's board of directors since October 2020.

## SEC filing metadata
- accession: 0001558370-21-016940
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2021-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/kala-20211216x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-016940
- JSON: https://secwatch.observer/filing/0001558370-21-016940.json
- Plain text: https://secwatch.observer/filing/0001558370-21-016940.txt

## Key facts
- Executive change
  Mark Iwicki changed role as President at KALA BIO, Inc..
  - Action: will no longer serve as
  - Role: President
  source text: Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm
- Executive change
  Todd Bazemore was appointed as President and Chief Operating Officer at KALA BIO, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837021016940/0001558370-21-016940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.